{"id":"insulin-regular-act-rapid","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Lipodystrophy"},{"rate":null,"effect":"Weight gain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Regular insulin is a short-acting human insulin that mimics endogenous insulin secretion. It binds to insulin receptors on muscle, fat, and liver cells, facilitating glucose transport into cells and promoting glycogen synthesis while inhibiting gluconeogenesis. This results in rapid reduction of blood glucose levels, typically beginning within 30 minutes of injection.","oneSentence":"Regular insulin binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:22.859Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus (when oral agents are insufficient)"}]},"trialDetails":[{"nctId":"NCT04726631","phase":"NA","title":"Insulin in Treatment of Diabetes Mellitus With Pregnancy","status":"COMPLETED","sponsor":"Assiut University","startDate":"2015-01-01","conditions":"Diabetes","enrollment":110},{"nctId":"NCT01594060","phase":"PHASE4","title":"Basal Bolus vs. Sliding Scale for Treatment of Diabetic Patients in Medical Wards","status":"COMPLETED","sponsor":"HaEmek Medical Center, Israel","startDate":"2012-06","conditions":"Diabetes Mellitus Type 2","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":227,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Insulin, regular - act rapid","genericName":"Insulin, regular - act rapid","companyName":"HaEmek Medical Center, Israel","companyId":"haemek-medical-center-israel","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Regular insulin binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus (when oral agents are insufficient).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}